Treatment Outcomes of Patients with Localized Anal Squamous Cell Carcinoma and HIV Infection: Systematic Review and Meta-Analysis

Date 21 October 2018
Event ESMO 2018 Congress
Session Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Topics Anal Cancer
Presenter Marcos Camandaroba
Citation Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281
Authors M. Camandaroba1, R. Riechelmann1, V. Silva1, C. Mello1, R. Araujo2
  • 1Oncology, A. C. Camargo Cancer Center, 01509-010 - Sao Paulo/BR
  • 2Upper Gi And Hpb Surgery, Barretos Cancer Hospital, 14784-400 - São Paulo/BR



Definitive chemoradiation (CRT) is the standard treatment for localized squamous cell carcinoma of the anus (SCCA). Because most phase III trials in SCCA have excluded patients with HIV, the evidence on treatment outcomes of these patients is lacking. We performed a systematic review and meta-analysis on the efficacy and toxicity profiles of HIV-positive SCCA patients treated with definitive CRT.


The systematic search was conducted Embase, Medline, Cochrane Libary, Scopus, Lilacs and Opengrey, from inception until September 2017. Eligible studies were clinical trials, prospective or retrospective cohorts studies. The main outcome variables were 3-year disease-free (DFS) and overall survival (OS) rates and frequency of grade 3 or 4 (G3/4) treatment-related toxicities, according to HIV status. Meta-analyses using pooled risk ratios were performed for binary outcomes from comparative studies from the antiretroviral therapy era with random and fixed effects models.


Out of 3,951 studies, 40 were deemed eligible, with a total of 3,720 patients. One third (N = 1,298; 34%) were HIV-positive and their median pre CRT CD4 count was 347 um/L. HIV-positive patients presented trends for higher risk of G3/4 cutaneous toxicities (Risk Ratio [RR]: 1.56,95% [CI] 0.98-2.48;p0.061; I2= 77%), G3/4 leukopenia (RR: 1.28, 95% [CI] 0.96-1.70; p = 0.088; I2= 0%) and inferior 3-year DFS rate (RR: 1.52, 95% [CI] 0.99-2.33, p = 0.057; I2= 52.19%), and significantly worse 3-year OS rate (RR: 1.64, 95% [CI] 1.27-2.11,p< 0.001; I2= 0%).


Patients with localized SCCA and HIV infection treated with CRT tend to experience higher risk of toxicities and worse DFS and OS rates. Our findings suggest that future trials should be tailored to HIV-positive patients.

Clinical trial identification

Legal entity responsible for the study

Rachel Riechelmann.


Has not received any funding.

Editorial Acknowledgement


All authors have declared no conflicts of interest.